[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-346780-105":59,"doc-detail-346780-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","emerging-immune-checkpoint-targets-and-combination-strategies-in-blood-cancer-immunotherapy","Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy","","Immunotherapy has transformed cancer care by enabling durable responses across multiple malignancies, yet blood cancers remain challenging due to pronounced heterogeneity, an immunosuppressive tumor microenvironment (TME), and strong immune-evasion mechanisms. This review consolidates current immune checkpoint blockade (ICB) knowledge, assessing both established agents and emerging targets such as LAG-3, TIM-3, and CD47 in hematologic malignancies. It evaluates how cancer stem cells drive treatment resistance and relapse through aberrant pathways including Wnt, Notch, and m6A, and it examines the potential and design principles of cellular immunotherapies including CAR-T and CAR-NK to improve persistence and safety. Integrating preclinical and clinical evidence, it outlines rational multi-pronged combination strategies that disrupt a “resistance ecosystem” and support personalized curative regimens for blood cancer patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/emerging-immune-checkpoint-targets-and-combination-strategies-in-blood-cancer-immunotherapy/346780/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/emerging-immune-checkpoint-targets-and-combination-strategies-in-blood-cancer-immunotherapy/346780.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are blood cancers especially difficult for immunotherapy despite advances in cancer treatment?","Question",{"text":112,"@type":113},"Blood cancers show major heterogeneity and an immunosuppressive tumor microenvironment (TME), along with potent immune-evasion mechanisms that limit durable benefit.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which emerging immune checkpoint targets are discussed for hematologic malignancies?",{"text":117,"@type":113},"The review highlights immune checkpoint targets including LAG-3, TIM-3, and CD47, alongside established immune checkpoint blockade agents.",{"name":119,"@type":110,"acceptedAnswer":120},"How do cancer stem cells and related signaling pathways contribute to therapeutic resistance and recurrence?",{"text":121,"@type":113},"Cancer stem cells are described as driving resistance and relapse, supported by aberrant signaling pathways such as Wnt, Notch, and m6A that promote immune avoidance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},346780,1790193965,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Annals of Hematology (2026) 105:215  \n[https://doi.org/10.1007/s00277-026-06919-z](https://doi.org/10.1007/s00277-026-06919-z)  \nREVIEW  \nEmerging immune checkpoint targets and combination strategies in blood cancer immunotherapy  \nMutaz Jamal Al-khreisat1 · Waleed K. Abdulsahib2 · Ihsan Khudhair Jasim3 · H. Malathi4 · Pradeepta Sekhar Patro5 ·  \nD. Alex Anand6 · Gunjan Mukherjee7 · Aashna Sinha8 · Dilnoz Buriyeva9  \nReceived: 27 November 2025 / Accepted: 23 February 2026 / Published online: 31 March 2026 © The Author(s) 2026  \nAbstract  \nImmunotherapy has revolutionized cancer treatment, offering durable responses across various malignancies. However, blood cancers present unique challenges due to significant heterogeneity, an immunosuppressive tumor microenvironment (TME), and potent mechanisms of immune evasion. This review synthesizes the current landscape of immune checkpoint blockade (ICB), evaluating both established agents and emerging targets (e.g., LAG-3, TIM-3, CD47) in hematologic malignancies. We critically examine the role of cancer stem cells (CSCs) in driving therapeutic resistance and recurrence, highlighting how aberrant signaling pathways (Wnt, Notch, m6A) fuel immune avoidance. Furthermore, we assess the transformative potential of cellular immunotherapies, specifically CAR-T and CAR-NK cells, proposing strategies to enhance their persistence and safety. By integrating insights from recent preclinical and clinical studies, this report provides a roadmap for developing rational, multi-pronged combination strategies that disrupt the “resistance ecosystem” of blood cancers, paving the way for personalized curative regimens.  \nKeywords Immune checkpoint targets · Blood cancers · Tumor microenvironment · Cancer stem cells · Combination immunotherapy  \n􀀍 Waleed K. Abdulsahib [waleedk.abdulsahib@uoalfarahidi.edu.iq](waleedk.abdulsahib@uoalfarahidi.edu.iq)  \nMutaz Jamal Al-khreisat  \n[m.alkhreisat@ammanu.edu.jo](m.alkhreisat@ammanu.edu.jo)  \nIhsan Khudhair Jasim  \n[ihsan.khudhair@uoturath.edu.iq](ihsan.khudhair@uoturath.edu.iq)  \nH. Malathi  \n[h.malathi@jainuniversity.ac.in](h.malathi@jainuniversity.ac.in)  \nPradeepta Sekhar Patro  \n[pradeeptasekharpatro@soa.ac.in](pradeeptasekharpatro@soa.ac.in)  \nD. Alex Anand  \n[alexanand.bioinfo@sathyabama.ac.in](alexanand.bioinfo@sathyabama.ac.in)  \nGunjan Mukherjee  \n[drgunjanmukherjee@outlook.com](drgunjanmukherjee@outlook.com)  \nAashna Sinha  \n[aashna07sinha@gmail.com](aashna07sinha@gmail.com)  \nDilnoz Buriyeva  \n[buriyevadilnoz29@gmail.com](buriyevadilnoz29@gmail.com)  \n1 Faculty of Allied Medical Sciences, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan  \n2 Department of Pharmacology and Toxicology, College of Pharmacy, Al Farahidi University, Baghdad, Iraq  \n3 Department of Pharmaceutics, Faculty of Pharmacy, AlTurath University, Baghdad, Iraq  \n4 Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India  \n5 Department of Immunology, IMS and SUM Hospital, Siksha’O’Anusandhan, Bhubaneswar 751003, Odisha, India  \n6 Department of Biomedical, Sathyabama Institute of Science and Technology, Chennai, Tamil Nadu, India  \n7 University Institute of Biotechnology, Chandigarh University, Mohali, Punjab, India  \n8 School of Applied and Life Sciences, Division of Research and Innovation, Uttaranchal University, Dehradun, Uttarakhand, India  \n9 Department of Medicine, Termez University of Economics and Serviсe, Termez, Uzbekistan  \nIntroduction  \nThe pursuit of effective cancer therapies has yielded transformative breakthroughs, most notably the advent of immunotherapy. For patients with hematologic malignancies, harnessing the host immune system offers a beacon of hope where conventional chemotherapy and radiation often fail [1] . However, despite the clinical success of approved agents, a significant subset of patients experiences disease progression or relapse, largely attribu","cbCaifkgrUC9mGt7","https://ap.wps.com/l/cbCaifkgrUC9mGt7","pdf",1679016,14,"English","# Abstract\n# Introduction\n## Immune checkpoint blockade responses and resistance in hematologic malignancies\n## Rationale for targeting the resistance ecosystem and emerging combination strategies","[{\"question\":\"Why are blood cancers especially difficult for immunotherapy despite advances in cancer treatment?\",\"answer\":\"Blood cancers show major heterogeneity and an immunosuppressive tumor microenvironment (TME), along with potent immune-evasion mechanisms that limit durable benefit.\"},{\"question\":\"Which emerging immune checkpoint targets are discussed for hematologic malignancies?\",\"answer\":\"The review highlights immune checkpoint targets including LAG-3, TIM-3, and CD47, alongside established immune checkpoint blockade agents.\"},{\"question\":\"How do cancer stem cells and related signaling pathways contribute to therapeutic resistance and recurrence?\",\"answer\":\"Cancer stem cells are described as driving resistance and relapse, supported by aberrant signaling pathways such as Wnt, Notch, and m6A that promote immune avoidance.\"}]","Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy | PDF",1790062717,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/42fc17f10a187fa2aba9e9132705e907.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a236f3604cf2d0c1b292d73f792a0ad.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f029630cce3b17afe993099bc87b891c.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/363b14e902923804267b46c653023f51.webp",980,1301]